Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Liabilities: 2011-2024

Historic Total Liabilities for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $139.7 million.

  • Adma Biologics' Total Liabilities fell 13.37% to $137.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.5 million, marking a year-over-year decrease of 13.37%. This contributed to the annual value of $139.7 million for FY2024, which is 28.00% down from last year.
  • Adma Biologics' Total Liabilities amounted to $139.7 million in FY2024, which was down 28.00% from $194.0 million recorded in FY2023.
  • Adma Biologics' Total Liabilities' 5-year high stood at $196.5 million during FY2022, with a 5-year trough of $119.4 million in FY2020.
  • For the 3-year period, Adma Biologics' Total Liabilities averaged around $176.7 million, with its median value being $194.0 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 45.46% in 2022, then decreased by 28.00% in 2024.
  • Adma Biologics' Total Liabilities (Yearly) stood at $119.4 million in 2020, then climbed by 13.11% to $135.1 million in 2021, then surged by 45.46% to $196.5 million in 2022, then fell by 1.28% to $194.0 million in 2023, then fell by 28.00% to $139.7 million in 2024.